Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03529448Phase 1Completed

TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

Role: collaborator

NCT03248167Phase 1Completed

Cannabidiol as a Treatment for AUD Comorbid With PTSD

Role: collaborator

NCT03252756Phase 1Completed

Effects of Cannabidiol in Alcohol Use Disorder

Role: collaborator

NCT03549819Phase 3Unknown

Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Role: collaborator

NCT03805750Phase 1Completed

Trial of Cannabis for Essential Tremor

Role: collaborator

NCT03550352Phase 2Terminated

Cannabinoids in PLWHIV on Effective ART

Role: collaborator

NCT02983695Phase 1Completed

Cannabinoid Therapy for Pediatric Epilepsy

Role: collaborator

NCT02517424Phase 2Completed

Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder

Role: lead

All 8 trials loaded